Literature DB >> 17982059

Impact of CD40 ligand, B cells, and mast cells in peanut-induced anaphylactic responses.

Jiangfeng Sun1, Katherine Arias, David Alvarez, Ramzi Fattouh, Tina Walker, Susanna Goncharova, Bobae Kim, Susan Waserman, Jennifer Reed, Anthony J Coyle, Manel Jordana.   

Abstract

The effector immune mechanisms underlying peanut-induced anaphylaxis remain to be fully elucidated. We investigated the relative contribution of Igs, mast cells (MCs), and FcepsilonRI in the elicitation of anaphylaxis in a murine model. Assessment of peanut hypersensitivity reactions was performed clinically and biologically. Our data show that wild-type (WT; C57BL/6 strain) mice consistently developed severe anaphylaxis (median clinical score: 3.5/5), an approximately 8 degrees C drop in core body temperature, and significantly increased plasma levels of histamine and leukotrienes. CD40 ligand- and B cell-deficient mice presented evidence of allergic sensitization as demonstrated by production of Th2-associated cytokines by splenocytes and a late-phase inflammatory response that were both indistinguishable to those detected in WT mice. However, CD40 ligand- and B cell-deficient mice did not exhibit any evidence of anaphylaxis. Our data also show that MC-deficient (Kit(W)/Kit(W-v)) mice did not suffer, unlike their littermate controls, anaphylactic reactions despite the fact that serum levels of peanut-specific Igs were similarly elevated. Finally, FcepsilonRI-deficient mice experienced anaphylactic responses although to a significantly lesser degree than those observed in WT mice. Thus, these data demonstrate that the presence of peanut-specific Abs along with functional MCs comprise a necessary and sufficient condition for the elicitation of peanut-induced anaphylaxis. That the absence of FcepsilonRI prevented the development of anaphylaxis only partially insinuates the contribution of an IgE-independent pathway, and suggests that strategies to impair MC degranulation may be necessary to improve the efficacy of anti-IgE therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17982059     DOI: 10.4049/jimmunol.179.10.6696

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  41 in total

Review 1.  Mediators released during human anaphylaxis.

Authors:  Shelley F Stone; Simon G A Brown
Journal:  Curr Allergy Asthma Rep       Date:  2012-02       Impact factor: 4.806

Review 2.  Approaches for analyzing the roles of mast cells and their proteases in vivo.

Authors:  Stephen J Galli; Mindy Tsai; Thomas Marichal; Elena Tchougounova; Laurent L Reber; Gunnar Pejler
Journal:  Adv Immunol       Date:  2015-02-07       Impact factor: 3.543

Review 3.  Potential effector and immunoregulatory functions of mast cells in mucosal immunity.

Authors:  L L Reber; R Sibilano; K Mukai; S J Galli
Journal:  Mucosal Immunol       Date:  2015-02-11       Impact factor: 7.313

4.  Group 2 Innate Lymphoid Cells Promote Development of T Follicular Helper Cells and Initiate Allergic Sensitization to Peanuts.

Authors:  James W Krempski; Takao Kobayashi; Koji Iijima; Andrew N McKenzie; Hirohito Kita
Journal:  J Immunol       Date:  2020-05-04       Impact factor: 5.422

Review 5.  Mucosal immunology of tolerance and allergy in the gastrointestinal tract.

Authors:  Lauren Steele; Lloyd Mayer; M Cecilia Berin
Journal:  Immunol Res       Date:  2012-12       Impact factor: 2.829

Review 6.  IgE receptor signaling in food allergy pathogenesis.

Authors:  Hans C Oettgen; Oliver T Burton
Journal:  Curr Opin Immunol       Date:  2015-09-18       Impact factor: 7.486

7.  Future Therapies for IgE-Mediated Food Allergy.

Authors:  M Cecilia Berin
Journal:  Curr Pediatr Rep       Date:  2014-06-01

Review 8.  The immunology of food allergy.

Authors:  Laura K Johnston; Karen B Chien; Paul J Bryce
Journal:  J Immunol       Date:  2014-03-15       Impact factor: 5.422

9.  T helper cell IL-4 drives intestinal Th2 priming to oral peanut antigen, under the control of OX40L and independent of innate-like lymphocytes.

Authors:  D K Chu; Z Mohammed-Ali; R Jiménez-Saiz; T D Walker; S Goncharova; A Llop-Guevara; J Kong; M E Gordon; N G Barra; A E Gillgrass; H Van Seggelen; W I Khan; A A Ashkar; J L Bramson; A A Humbles; R Kolbeck; S Waserman; M Jordana
Journal:  Mucosal Immunol       Date:  2014-04-30       Impact factor: 7.313

10.  Displaying Fel d1 on virus-like particles prevents reactogenicity despite greatly enhanced immunogenicity: a novel therapy for cat allergy.

Authors:  Nicole Schmitz; Klaus Dietmeier; Monika Bauer; Melanie Maudrich; Stefan Utzinger; Simone Muntwiler; Philippe Saudan; Martin F Bachmann
Journal:  J Exp Med       Date:  2009-08-10       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.